Monitoring treatment response by the hepatitis C virus core antigen assay.
Lindh
M
M
Department of Clinical Virology, Göteborg University, Guldhedsgatan 10B, 41346, Göteborg, Sweden. magnus.lindh@microbio.gu.se
Lagging
M
M
Westin
J
J
Wejstål
R
R
Norkrans
G
G
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D018936:Hepatitis C Antigens / Q000097:blood*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D011933:Reagent Kits, Diagnostic; D012044:Regression Analysis; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D014758:Viral Core Proteins / Q000097:blood*
D000998:Antiviral Agents; D018936:Hepatitis C Antigens; D016898:Interferon-alpha; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic; D014758:Viral Core Proteins; C069130:nucleocapsid protein, Hepatitis C virus; D012254:Ribavirin